Accuray (NASDAQ:ARAY) Issues Earnings Results

Accuray (NASDAQ:ARAY) released its quarterly earnings data on Wednesday. The medical equipment provider reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.03, Zacks reports. Accuray had a negative return on equity of 36.93% and a negative net margin of 3.72%. Accuray updated its FY 2025 guidance to EPS.

Accuray Stock Performance

Shares of ARAY opened at $2.49 on Thursday. The firm has a market capitalization of $250.41 million, a P/E ratio of -14.65 and a beta of 1.51. Accuray has a 52 week low of $1.40 and a 52 week high of $2.95. The stock has a 50 day moving average price of $2.10 and a two-hundred day moving average price of $1.97. The company has a debt-to-equity ratio of 3.59, a quick ratio of 0.87 and a current ratio of 1.63.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered shares of Accuray from a “buy” rating to a “hold” rating in a research note on Friday, November 15th.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.